CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1

Neuro-Oncology

Volumn 12, Issue 7, 2010, Pages 701-710

  Sciumé, Giuseppe ^a   Soriani, Alessandra ^a   Piccoli, Mario ^a   Frati, Luigi ^a   Santoni, Angela ^a   Bernardini, Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CX3CL1; CX3CR1; Glioma; Invasion; TGF beta1

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL AGGREGATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CX3CL1; DOWN-REGULATION; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78650290339     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop076     Document Type: Article

References (40)

1. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech. 2001;52:401-410.
2. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148:1404-1410.
3. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun. 2000;268:607-611.
4. Rooprai HK, Rucklidge GJ, Panou C, Pilkington GJ. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer. 2000;82:52-55.
5. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membranebound chemokine with a CX3C motif. Nature. 1997;385:640-644.
6. Nishimura M, Umehara H, Nakayama T, et al. Dual functions of fractalkine/ CX3C ligand 1 in trafficking of perforin + /granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002;168:6173-6180.
7. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost. 2007;97:694-703.
8. Schwaeble WJ, Stover CM, Schall TJ, et al. Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett. 1998;439:203-207.
9. Hulshof S, van Haastert ES, Kuipers HF, et al. CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol. 2003;62:899-907.
10. Lindia JA, McGowan E, Jochnowitz N, Abbadie C. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain. 2005;6:434-438.
11. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem. 2002;82:1311-1329.
12. Ambrosini E, Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res. 2004;29:1017-1038.
13. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics. 2007;4:590-601.
14. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev. 2005;48: 16-42.
15. Lauro C, Di Angelantonio S, Cipriani R, et al. Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J Immunol. 2008;180:7590-7596.
16. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277:49481-49487.
17. Kouno J, Nagai H, Nagahata T, et al. Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. J Neurooncol. 2004;70:301-307.
18. Nitta T, Allegretta M, Okumura K, Sato K, Steinman L. Neoplastic and reactive human astrocytes express interleukin-8 gene. Neurosurg Rev. 1992;15:203-207.
19. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer. 1994;58:240-247.
20. Ludwig A, Schulte A, Schnack C, et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem. 2005;93:1293-1303.
21. Zeng Y, Jiang J, Huebener N, et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 2005;228:187-193.
22. Calogero A, Lombari V, De Gregorio G, et al. Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int. 2004;4:1.
23. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64: 7596-7603.
24. Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S, Santoni A. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood. 2008;111:3626-3634.
25. Bernardini G, Spinetti G, Ribatti D, et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood. 2000;96:4039-4045.
26. Ehtesham M, Winston JA, Kabos P, Thompson RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene. 2006;25:2801-2806.
27. Zhou Y, Zhang J, Liu Q, et al. The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis. 2005;26:2058-2068.
28. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone. 2006;38:497-508.
29. Bierie B, Chung CH, Parker JS, et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009;119:1571-1582.
30. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA. 1998;95:10896-10901.
31. Franitza S, Kollet O, Brill A, et al. TGF-beta1 enhances SDF-1alpha-induced chemotaxis and homing of naive T cells by up-regulating CXCR4 expression and downstream cytoskeletal effector molecules. Eur J Immunol. 2002;32:193-202.
32. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362-374.
33. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121:727-735.
34. Barreiro O, de la Fuente H, Mittelbrunn M, Sanchez-Madrid F. Functional insights on the polarized redistribution of leukocyte integrins and their ligands during leukocyte migration and immune interactions. Immunol Rev. 2007;218:147-164.
35. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 2004;64:4693-4698.
36. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006;17:945-951.
37. Marchesi F, Piemonti L, Fedele G, et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008;68:9060-9069.
38. Lavergne E, Combadiere B, Bonduelle O, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res. 2003;63:7468-7474.
39. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 2005;26:41-47.
40. Liu C, Luo D, Streit WJ, Harrison JK. CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J Neuroimmunol. 2008;198:98-105.